Table 3.
Secondary Screening After Primary LBC Screening, % (95% CI)
| Triage Test | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|
| CIN2+ | ||||
| ASC-US/hrHPV+, ≥LSIL | 90.4 (81.9–95.7) | 78.8 (76.3–81.2) | 26.0 (23.5–28.6) | 74.0 (71.4–76.5) |
| ASC-US/HPV 16/18+, ≥LSIL | 78.3 (67.9–86.6) * | 85.3 (83.1–87.3) ** | 28.4 (22.7–34.8) | 71.6 (65.2–77.3) |
| ASC-US/p16+, ≥LSIL | 85.5 (75.7–92.0) | 84.4 (82.1–86.4) ** | 20.5 (18.2–22.9) | 79.5 (77.1–81.8) |
| CIN3+ | ||||
| ASC-US/hrHPV+, ≥LSIL | 97.6 (87.1–99.9) | 76.6 (74.0–79.0) | 26.0 (23.5–28.6) | 74.0 (71.4–76.4) |
| ASC-US/HPV 16/18+, ≥LSIL | 95.1 (83.5–99.4) | 83.6 (81.3–85.7) ** | 19.1 (17.0–21.5) | 80.9 (78.5–83.0) |
| ASC-US/p16+, ≥LSIL | 97.6 (85.6–99.9) | 82.3 (79.9–84.4) ** | 20.5 (18.2–22.9) | 79.5 (77.1–81.8) |
Notes: Significant McNemar’s test comparing to “ASC-US/hrHPV+, ≥LSIL”, *P<0.01. **P<0.001
Abbreviations: LSIL, low-grade squamous intraepithelial lesions; ASC-US, atypical squamous cells of undetermined significance; CIN2+/CIN3+, cervical intraepithelial neoplasia 2/3 or worse; CI, confidence interval; hrHPV, high-risk HPV; PPV, positive predictive value, NPV, negative predictive value.